Molecular classification of aggressive lymphomas—past, present, future

Abstract

Aggressive large B‐cell lymphomas (LBCLs) represent a frequent but clinically and molecularly heterogeneous group of tumors. Technological advances over the last decades prompted the development of different classification schemas to either sharpen diagnoses, dissect molecular heterogeneity, predict outcome, or identify rational treatment targets. Despite increased diagnostic precision and a noticeably improved molecular understanding of these lymphomas, clinical perspectives of patients largely remain unchanged. Recently, finished comprehensive genomic studies discovered genetically defined LBCL subtypes that predict outcome, provide insight into lymphomagenesis, and suggest rational therapies with the hope of generating patient‐tailored treatments with increased perspective for patients in greatest need. Current and future efforts integrate multiomics studies and/or leverage single‐cell technologies and will provide us with an even more fine‐grained picture of LBCL biology. Here, we highlight examples of how high‐throughput technologies aided in a better molecular understanding of LBCLs and provide examples of how to select rationally designed targeted treatment approaches that might personalize LBCL treatment and eventually improve patients perspective in the near future.